Stockscreener 앱 받기
0.7524
16.54%
-0.1491
Scinai Immunotherapeutics Ltd Adr 주식(SCNI)의 최신 뉴스
Scinai files prospectus for resale of 2.7 million ADSs - scanx.trade
Scinai Immunotherapeutics regains Nasdaq compli... - Pluang
Scinai Regains Compliance with Nasdaq Minimum Bid Price Requirement - PR Newswire
Nasdaq closes Scinai's $1 stock-price matter after 19 business days - Stock Titan
Scinai Immunotherapeutics (SCNI) Edges Higher to $1.71 as Biotech Micro-Cap Holds Key SupportWave Extension - dars.gov.et
Scinai Immunotherapeutics refocuses capital on NanoAb platform and CDMO business - TipRanks
Scinai Concludes PC111 Arrangements and Refocuses Capital on NanoAb Platform and Growing CDMO Business - Barchart.com
Scinai (NASDAQ: SCNI) updates $15M equity deal that could dilute investors - Stock Titan
Earnings call transcript: Scinai posts H1 2026 revenue growth as losses persist - Investing.com Nigeria
Earnings call transcript: Scinai posts H1 2026 revenue growth as losses persist - Investing.com
Scinai reports H1 2026 results, announces U.S. customer expansion - Investing.com India
Scinai Immunotherapeutics (NASDAQ: SCNI): Why Is A recent reverse share split that reset the chart structure in Focus Now? - Kalkine Media
Scinai (SCNI) Technicals: Ends Down by 5.59% at $3.04 in the Current Update; Levels: $2.89 and $3.19 Define the Nearby Reference Levels in the Latest ReadingFactor Valuation - careplusvn.com
Scinai (SCNI) Technicals: Ends Down by 5.59% at $3.04 in the Current Update; Levels: $2.89 and $3.19 Define the Nearby Reference Levels in the Latest ReadingTriangle Correction - dars.gov.et
Scinai reports H1 2026 results, announces U.S. customer expansion - Investing.com
Scinai (SCNI) Technicals: Ends Down by 5.59% at $3.04 in the Current Update; Levels: $2.89 and $3.19 Define the Nearby Reference Levels in the Latest ReadingOversold Bounce Ideas - dars.gov.et
Scinai (SCNI) Earnings Update: EPS Beats Its Estimate in the Latest Session; Price Move - dars.gov.et
What Could Scinai Immunotherapeutics (NASDAQ:SCNI) Reveal Today About Its Next Operating Milestones? - Kalkine Media
Scinai Immunotherapeutics Sets 1-for-10 ADS Ratio Change to Support Nasdaq Compliance - The Globe and Mail
Scinai Immunotherapeutics Sets 1-for-10 ADS Ratio Change to Support Nasdaq Compliance - TipRanks
Scinai (NASDAQ: SCNI) turns to reverse split to chase Nasdaq $1 minimum - Stock Titan
Scinai (SCNI) Latest Results Brief: EPS Exceeds Its Estimate at the Close; Post-Earnings Trading: Shares Finish 2.44% Up on the DayDividend Increase Stocks - dars.gov.et
Scinai (SCNI) Latest Results Brief: EPS Exceeds Its Estimate at the Close; Post-Earnings Trading: Shares Finish 2.44% Up on the DayEarnings Miss Streak - dars.gov.et
Scinai (SCNI) Latest Results Brief: EPS Exceeds Its Estimate at the Close; Post-Earnings Trading: Shares Finish 2.44% Up on the DayAnalyst Coverage Count - dars.gov.et
Scinai Strengthens CDMO Leadership with Appointment of Eran Kuratz as Head of Supply Chain and Business Process Administration - Barchart.com
Scinai Immunotherapeutics (SCNI) Slips 6.6% as Shares Test Key Support at $0.25Volatility Stop - careplusvn.com
Scinai Immunotherapeutics (SCNI) Slips 2.41% as Stock Hovers Near Key Support at $0.24Wedge Breakout - dars.gov.et
Scinai Immunotherapeutics (SCNI) Edges Higher Amid Tight Trading RangeCharm Flow - careplusvn.com
Scinai Immunotherapeutics (SCNI) Edges Higher Amid Tight Trading RangeGap Fill Strategy - dars.gov.et
Scinai Immunotherapeutics Ltd. (SCNI) Edges Higher in Tight Range as Support and Resistance Levels HardenRisk Reward Setups - careplusvn.com
Scinai Immunotherapeutics Q4 2023 Earnings: EPS Surprises to the Upside Despite No Revenue; Stock DeclinesShare Dilution Risk - careplusvn.com
Scinai Immunotherapeutics Q4 2023 Earnings: EPS Surprises to the Upside Despite No Revenue; Stock Declines - dars.gov.et
Scinai Immunotherapeutics Q4 2023 Earnings: EPS Surprises to the Upside Despite No Revenue; Stock DeclinesLow Growth Earnings - dars.gov.et
SCNIScinai Immunotherapeutics Ltd ADR Latest SEC Filings - Finviz
SCNIScinai Immunotherapeutics Ltd ADR Options - Finviz
Scinai Immunotherapeutics Ltd. Sponsored ADR Actuals & Estimates (NASDAQ:SCNI) - TradingView
Price to sales forward of Scinai Immunotherapeutics Ltd. Sponsored ADR – MUN:2F5 - TradingView
Enterprise value to revenue forward of Scinai Immunotherapeutics Ltd. Sponsored ADR – MUN:2F5 - TradingView
Enterprise value to EBITDA forward of Scinai Immunotherapeutics Ltd. Sponsored ADR – MUN:2F5 - TradingView
Enterprise value to EBIT forward of Scinai Immunotherapeutics Ltd. Sponsored ADR – MUN:2F5 - TradingView
Why Scinai Immunotherapeutics stock is skyrocketing 90% higher today - MSN
Why Scinai Immunotherapeutics stock is skyrocketing 90% higher today - MSN
Scinai Reports First Quarter 2026 Financial Results and Provides Corporate Update Highlighting Expansion of CDMO Platform and Advancement of Strategic Growth Initiatives - Barchart.com
Scinai Reports First Quarter 2026 Financial Results and Provides Corporate Update Highlighting Expansion of CDMO Platform and Advancement of Strategic Growth Initiatives - Sahm
SCNI - Finviz
SCNI Technical Analysis | Trend, Signals & Chart Patterns | SCINAI IMMUNOTHERAPEUTICS LT (NASDAQ:SCNI) - ChartMill
Scinai appoints Eilon Elmalem as Yavne CDMO facility head - Investing.com
Scinai appoints Eilon Elmalem as Yavne CDMO facility head By Investing.com - Investing.com India
Scinai Biopharma Services Appoints Eilon Elmalem as Site Head of Yavne CDMO Facility - Barchart.com
Scinai Immunotherapeutics to Lead Strategic Roundtable Discussion on Oral Therapies and the Future of Biologics at the 7th Dermatology Drug Development Summit Europe - Sahm
4.22%
자본화:
|
볼륨(24시간):